Study guide
12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch
CCI Registered Cardiac Sonographer RCS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: RCS Orientation and Clinical Context
1.1 RCS Identity, Exam Format, Application, and Retesting 1.2 Clinical History, Symptoms, Indications, and Risk Factors 1.3 Prior Studies, Serial Change, and Cross-Modality Context
2 Chapter 2: Orders, Safety, and Patient Preparation
2.1 Order Verification, Scope, and Protocol Selection 2.2 Sonographer Ergonomics and Staff Safety 2.3 Patient Preparation, Positioning, Consent, Infection Control, and Aftercare
3 Chapter 3: Reporting and 2-D TTE Foundations
3.1 Structured Findings, Significant Results, and Escalation 3.2 Standard 2-D TTE Windows, Views, and Acquisition Sequence 3.3 2-D Measurements, Foreshortening, Image Quality, and QA
4 Chapter 4: M-Mode and Doppler Acquisition
4.1 M-Mode Alignment, Timing, Measurements, and Pitfalls 4.2 Color Doppler Acquisition, Scale, Gain, and Jet Display 4.3 PW and CW Spectral Doppler Acquisition
5 Chapter 5: Advanced Doppler and Contrast
5.1 Tissue Doppler and Hemodynamic Sample Placement 5.2 Ultrasound-Enhancing Agents and LV Opacification 5.3 Agitated-Saline Studies and Intracardiac Shunts
6 Chapter 6: Stress Echocardiography
6.1 Exercise Stress Echo Protocols and Peak Imaging 6.2 Pharmacologic Stress Echo, Dobutamine, and Safety 6.3 Non-Ischemic Stress Echo and Hemodynamic Provocation
7 Chapter 7: TEE, Strain, and 3-D TEE
7.1 Assisting TEE: Preparation, Probe Safety, Views, and Complications 7.2 Strain Acquisition, Tracking Quality, and Reproducibility 7.3 3-D TEE Acquisition, Cropping, Orientation, and Artifacts
8 Chapter 8: 3-D TTE and the Aortic Valve
8.1 3-D TTE Full-Volume Acquisition and Quantitation 8.2 Aortic-Valve Anatomy, Morphology, and Function 8.3 Aortic Stenosis: Velocities, Gradients, Valve Area, and Flow States
9 Chapter 9: Aortic Regurgitation and Mitral Structure
9.1 Aortic Regurgitation Mechanisms and Integrated Severity 9.2 Mitral-Valve Anatomy, Motion, and Mechanisms 9.3 Mitral Stenosis: Planimetry, Gradients, Pressure Half-Time, and Suitability
10 Chapter 10: Mitral and Tricuspid Valve Findings
10.1 Mitral Regurgitation Mechanism, Quantitation, and Severity Integration 10.2 Tricuspid-Valve Anatomy, Structure, and Function 10.3 Tricuspid Stenosis Assessment
11 Chapter 11: Right-Sided Valve Disease
11.1 Tricuspid Regurgitation Mechanism and Severity 11.2 Pulmonic-Valve Anatomy, Structure, and Function 11.3 Pulmonic Stenosis Assessment
12 Chapter 12: Pulmonic Regurgitation and Prosthetic Valves
12.1 Pulmonic Regurgitation Mechanism and Severity 12.2 Normal Mechanical and Bioprosthetic Valve Assessment 12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch
13 Chapter 13: Endocarditis and Cardiac Chambers
13.1 Valvular Endocarditis, Vegetations, Abscess, and Complications 13.2 LV and LA Size, Geometry, Volumes, Mass, and Function 13.3 RV and RA Size, Pressure, Volume, and Function
14 Chapter 14: Cardiomyopathy Phenotypes and Diastology
14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction 14.2 Restrictive, Arrhythmogenic, and Stress Cardiomyopathies 14.3 Diastolic Function, Filling Pressure, Grading, and Pitfalls
15 Chapter 15: Systolic Function and Ischemia
15.1 LV Systolic Function, Simpson EF, Regional Motion, and Output 15.2 RV Systolic Function: TAPSE, S-prime, FAC, and Coupling 15.3 Ischemic Heart Disease, Coronary Territories, Stress Response, and Complications
16 Chapter 16: Pericardium and Great Vessels
16.1 Pericardial Effusion, Tamponade, Constriction, and Doppler Physiology 16.2 Great Vessels, Venous Return, and Pulmonary Artery Assessment 16.3 Aortic Root, Aneurysm, Dissection, and Coarctation
17 Chapter 17: Pulmonary Pressure, Masses, and Congenital Recognition
17.1 Pulmonary Hypertension, RAP/PASP Estimation, and RV Consequences 17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics 17.3 Adult Recognition of ASD, VSD, PFO, PDA, and Congenital Clues
18 Chapter 18: Devices, Strain, and Hemodynamics
18.1 ICDs, Pacemakers, Occluders, Closure Devices, and Mechanical Support 18.2 Strain Interpretation, Global Longitudinal Strain, and Disease Patterns 18.3 Cardiac Hemodynamics, Bernoulli, Continuity, Stroke Volume, and Shunts
19 Chapter 19: Infiltrative Disease and Physics Foundations
19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns 19.2 Ultrasound Wave Properties, Propagation, Frequency, and Wavelength 19.3 Artifact Recognition: Reverberation, Shadowing, Mirror, Refraction, and Aliasing
20 Chapter 20: Resolution and Doppler Optimization
20.1 Axial/Lateral Resolution, Frame Rate, Depth, Focus, and Trade-Offs 20.2 Spectral Doppler Optimization, Nyquist, Filters, Gain, and Angle 20.3 Color Doppler Optimization, Scale, Priority, Variance, and Gain
21 Chapter 21: 2-D, 3-D, and Contrast Optimization
21.1 2-D Optimization: Frequency, Gain, TGC, Harmonics, Depth, and Focus 21.2 3-D Optimization: Volume Rate, Stitching, Cropping, and Display 21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts
12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch
Key Takeaways Explain This Topic AI
An elevated prosthetic gradient is a finding, not a mechanism; compare with the stable baseline and exclude high flow, tachycardia, PPM, pressure recovery, sampling error, and supra- or subvalvular obstruction.
Confirm obstruction with concordant flow-dependent and less flow-dependent Doppler evidence plus abnormal leaflet or occluder structure or motion, using TEE, CT, or fluoroscopy when TTE is limited.
Separate intravalvular from paravalvular regurgitation and expected washing flow, then integrate jet origin, circumferential extent, spectral and volumetric evidence, chamber response, and serial change.
PPM is a normally moving prosthesis whose EOA is too small for the patient's body size, usually present from baseline; acquired obstruction produces a new hemodynamic or structural change, though both can coexist.
Last updated: July 2026
Treat a high gradient as the start of the investigation
Retrieve valve type, size, position, implant date, procedure details, stable postoperative baseline, symptoms, anticoagulation history, fever or embolic events, BP, heart rate, rhythm, and body surface area. Repeat imaging if Doppler alignment, tracing, or PW location is questionable. A high gradient may reflect true obstruction, but also anemia, fever, pregnancy, sepsis, significant regurgitation, shunt, tachycardia, prosthesis–patient mismatch (PPM), supra- or subvalvular obstruction, pressure recovery, or the high-velocity central orifice of a bileaflet valve. Low flow can hide important obstruction.
Map velocity with PW proximal to the valve before CW interrogation, and acquire CW from every appropriate window. Compare velocity, mean gradient, contour, VTI, DVI, EOA, acceleration time for aortic valves, PHT for atrioventricular valves, and chamber response with baseline and device-specific references. A new rounded, late-peaking aortic envelope, prolonged acceleration, falling DVI or EOA, and rising gradient is more concerning than one isolated high value. Current ASE guidance requires at least one flow-dependent measure such as velocity or mean gradient and one less flow-dependent measure such as DVI or EOA to support significant prosthetic aortic stenosis.
Question Evidence to obtain Common alternative explanation
Is flow truly high? Stroke volume, anemia/fever context, other regurgitation or shunt Normal prosthesis passing excess flow
Is the narrowing valvar? PW localization, leaflet/occluder excursion, CW contour LVOT/RVOT, conduit-edge, or branch obstruction
Has function changed? Stable baseline and serial velocity, gradient, DVI, EOA Small valve with unchanged expected hemodynamics
Is the valve small for the patient? Indexed EOA and BMI-appropriate PPM criteria Acquired thrombus, pannus, or degeneration
Is imaging adequate? Multiple 2-D/3-D planes and complementary modality Shadow, reverberation, or incorrect sample position
For surgical aortic prostheses, a rounded symmetric jet, acceleration time above 100 ms, acceleration-time/ejection-time ratio above 0.37, DVI below 0.25, EOA markedly below the type-size reference, and mean gradient at least 35 mmHg form a significant-obstruction pattern when flow and technique are appropriate. These are integrated markers, not independent verdicts. For a prosthetic mitral valve, a mean gradient above 10 mmHg at a normal heart rate, PHT above 200 ms, DVI above 2.5, and EOA below 1.0 cm² support significant stenosis, but tachycardia and important MR must be excluded and motion demonstrated. Right-sided prostheses require respiratory averaging, correct flow assumptions, and position-specific references.
Determine the pathologic category
Structural valve dysfunction is permanent intrinsic deterioration: bioprosthetic leaflet thickening, fibrosis, calcification, tear, stent deformation, or mechanical component failure. Nonstructural dysfunction includes PPM, paravalvular leak, malposition, entrapment, chamber or root dilation, and pannus. Thrombosis and endocarditis are separate categories that may cause obstruction, regurgitation, or both. Categories can coexist.
Thrombosis may present with new symptoms, embolism, altered mechanical sounds, a rising gradient, leaflet thickening, or reduced leaflet/occluder motion, especially with inadequate anticoagulation. TTE establishes hemodynamic change but often cannot distinguish thrombus from pannus by echogenicity. TEE can show atrial-side mitral thrombus and en-face motion; cine fluoroscopy measures mechanical opening and closing angles; gated CT depicts mechanical motion, pannus, thrombus, and hypoattenuated leaflet thickening in bioprostheses. Do not delay urgent communication for a stuck mechanical occluder or hemodynamic instability while pursuing perfect images.
Degeneration often evolves over years with progressive tissue thickening, calcification, restriction, or tear. Pannus is fibrous periannular ingrowth and tends to be fixed; thrombus can occur rapidly, but timing alone is not definitive. Vegetation, abscess, new paravalvular leak, or rocking suggests infection or dehiscence and requires prompt escalation. Compare with postoperative material so pledgets, sutures, and expected shadow are not mislabeled.
Localize regurgitation and distinguish PPM
First decide whether flow is expected physiologic leakage, abnormal intravalvular regurgitation through the prosthesis, or paravalvular regurgitation outside the sewing ring or stent. Sweep the whole circumference because shadow can hide jets and multiple leaks cannot be represented by one diameter. Integrate color origin and vena contracta, CW density and contour, flow convergence, downstream venous or arterial reversal, comparative stroke volumes, chamber remodeling, pulmonary pressure, and serial change. A rocking valve plus a new paravalvular jet is dehiscence until urgently evaluated. TEE with 3-D color is often best for mitral or tricuspid leak localization; CMR can quantify regurgitant volume when echo remains discordant.
PPM means the prosthesis is structurally normal and opens normally, but its EOA is too small relative to body size. Calculate indexed EOA = EOA / body surface area and apply position- and BMI-appropriate current thresholds; indexing can overstate aortic PPM in obesity. PPM is usually evident on the stable postoperative baseline and remains relatively stable. Acquired obstruction instead produces new restriction or worsening Doppler values. PPM can coexist with degeneration or thrombosis, and severe PPM can have a normal gradient during low flow, so neither timing nor gradient alone settles the diagnosis.
The final report identifies device and baseline, states acquisition quality, quantifies serial change, separates intra- from paravalvular regurgitation, describes motion and masses, lists competing causes of a high gradient, and names unresolved limitations. Recommend interpreter-directed TEE, CT, fluoroscopy, CMR, stress echo, or catheter hemodynamics when the clinical and TTE data remain discordant.
Before labeling interval obstruction, remeasure the LVOT at the original site and match heart rate, stroke volume, Doppler window, and beat selection; an altered PW sample alone can change DVI and calculated EOA.